Format

Send to

Choose Destination
Am J Public Health. 2008 Aug;98(8):1366-71. doi: 10.2105/AJPH.2007.124537. Epub 2008 Jun 12.

Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Author information

1
Johnson & Johnson Pharmaceutical Research & Development, 1125 Trenton-Harbourton Rd, PO Box 200, Mail Stop K-304, Titusville, NJ 08560, USA. jberlin@prdus.jnj.com

Abstract

Premarketing studies of drugs, although large enough to demonstrate efficacy and detect common adverse events, cannot reliably detect an increased incidence of rare adverse events or events with significant latency. For most drugs, only about 500 to 3000 participants are studied, for relatively short durations, before a drug is marketed. Systems for assessment of postmarketing adverse events include spontaneous reports, computerized claims or medical record databases, and formal postmarketing studies. We briefly review the strengths and limitations of each. Postmarketing surveillance is essential for developing a full understanding of the balance between benefits and adverse effects. More work is needed in analysis of data from spontaneous reports of adverse effects and automated databases, design of ad hoc studies, and design of economically feasible large randomized studies.

PMID:
18556607
PMCID:
PMC2446471
DOI:
10.2105/AJPH.2007.124537
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center